A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
166actual
Sites
74
Countries
Argentina, Australia, Bulgaria +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision; the decision is not related to any safety concern
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-06 | actual | When the study began enrolling |
| Primary completion | 2025-09-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-21 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Interventions
- Drug: Amlitelimab — also filed as SAR445229
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in Severity of Alopecia Tool (SALT) score at Week 36
measured Baseline to Week 36
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed